Immunotherapy added to chemo extended remission in advanced nasopharyngeal cancer

Adding the immunotherapy antibody tislelizumab to standard chemotherapy kept advanced nasopharyngeal cancer in check longer than chemotherapy alone: in a three-year update of the phase 3 RATIONALE-309 trial, median progression-free survival was 9.6 months with the drug added against 7.4 months with placebo [s1]. Patients who received tislelizumab also lived longer on average, but that overall-survival difference did not reach statistical significance in the main analysis, so the durable, established benefit here is delayed progression rather than proven longer life [s1].

Nasopharyngeal carcinoma — a cancer of the upper throat behind the nose — is uncommon in most of the world but far more frequent in parts of southern China and Southeast Asia [s1]. When it comes back or spreads, chemotherapy has been the mainstay and options are limited. RATIONALE-309 tested adding tislelizumab, a PD-1 checkpoint inhibitor developed in China, to first-line chemotherapy; this report extends the follow-up to roughly three years and looks for markers of who benefits most.

What they did

The double-blind trial ran at Asian centres from April 2019 to December 2023 and enrolled treatment-naive adults with recurrent or metastatic disease [s1][s2]. It randomly assigned 263 participants in a 1:1 ratio — 131 to tislelizumab and 132 to placebo — each given at 200 mg every three weeks alongside gemcitabine and cisplatin for four to six cycles [s1]. Of those enrolled, 206 (78.3%) were male and the median age was 50 years (range, 23 to 74) [s1]. Patients on placebo could cross over to tislelizumab if their cancer progressed — a humane design that also complicates the survival comparison, because it lets the control group receive the drug being tested [s1]. The primary endpoint was progression-free survival judged by an independent review committee [s1].

What it showed

At a median follow-up of 27.5 months, tislelizumab plus chemotherapy improved progression-free survival: a median of 9.6 months (95% confidence interval, 7.6 to 11.6) against 7.4 months (95% confidence interval, 5.6 to 7.6) with placebo, a hazard ratio of 0.53 (95% confidence interval, 0.39 to 0.71) [s1]. Median overall survival was 45.3 months with tislelizumab against 31.8 months with placebo — a large absolute gap — but the hazard ratio for death was 0.73 with a 95% confidence interval of 0.51 to 1.05, an interval that crosses 1 and so does not establish a survival benefit on its own [s1].

The authors report two analyses that try to correct for the crossover, since patients switching to the drug would tend to narrow the measured survival gap: a rank-preserving structural failure time analysis gave a hazard ratio of 0.56 (95% confidence interval, 0.27 to 1.19) and a two-stage adjusted analysis 0.62 (95% confidence interval, 0.40 to 0.97) [s1]. These suggest a larger underlying survival benefit, but they are modelling adjustments rather than the trial's primary comparison, and one of the two intervals still touches 1 — reason to treat the survival case as suggestive, not settled.

A biomarker finding points to who gains most: participants with high B-cell gene expression in their tumours had a greater survival benefit, with a hazard ratio of 0.41 (95% confidence interval, 0.23 to 0.74) [s1]. That is an exploratory signal from a subgroup, worth testing prospectively rather than acting on.

The cost side

Immune-mediated adverse events — the checkpoint inhibitor's signature toxicity, in which the unleashed immune system attacks healthy tissue — were more common with tislelizumab, at 53.4% versus 37.7% with placebo, though most were grade 1 or 2 [s1]. Rates of the most severe adverse events were broadly similar between the groups [s1].

What to watch

The trial was sponsored by tislelizumab's manufacturer, and this analysis is a secondary, longer-term look rather than a fresh primary readout [s1]. Its clearest result — a near-halving of the risk of progression — is consistent with what checkpoint inhibitors have done when added to chemotherapy across several cancers; its survival result needs the caveats above. The finding belongs to the same first-line, recurrent setting that differs from the earlier, curable stage where induction chemotherapy is given before radiotherapy, and it adds to a run of China-developed cancer immunotherapies now reshaping treatment, a trend that also raises questions about how such approvals travel across regulators.

Sources

• [s1] Yang Y, Yen C, Pan J, et al. First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer. JAMA Oncology. 26 February 2026.
• [s2] ClinicalTrials.gov. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Cancer (RATIONALE-309, NCT03924986). U.S. National Library of Medicine.